Key Points
- CFO Oluyemi Okupe sold 3,975 shares at an average price of $19.98 on April 6 for $79,420.50 under a pre‑arranged Rule 10b5‑1 plan, trimming his stake to 318,789 shares (a ~1.23% decrease) after larger sales in January and March.
- Hims & Hers stock is trading down (~3.9%) around $19.54, with a one‑year range of $13.74–$70.43, market cap of about $4.45B, and a 50‑day average ($20.26) well below the 200‑day average ($34.02), reflecting recent weakness.
- Operationally the company has a growth catalyst—an expanded Novo Nordisk GLP‑1 partnership and a new weight‑loss membership to boost prescription and recurring revenue—but faces risks from a potential tariff on drug sourcing and a recent third‑party customer‑service data breach.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 3,975 shares of the company's stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $19.98, for a total value of $79,420.50. Following the completion of the transaction, the chief financial officer owned 318,789 shares in the company, valued at $6,369,404.22. This represents a 1.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oluyemi Okupe also recently made the following trade(s):
- On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The shares were sold at an average price of $23.77, for a total value of $219,088.09.
- On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.34, for a total value of $275,092.78.
Hims & Hers Health Trading Down 3.9%
HIMS opened at $19.54 on Wednesday. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The stock has a market capitalization of $4.45 billion, a PE ratio of 38.31, a P/E/G ratio of 2.31 and a beta of 2.32. The business's 50 day moving average price is $20.26 and its 200 day moving average price is $34.02. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.06. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm had revenue of $617.82 million for the quarter, compared to analysts' expectations of $619.48 million. During the same period in the prior year, the firm posted $0.11 earnings per share. The firm's quarterly revenue was up 28.4% on a year-over-year basis. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the business. Quent Capital LLC purchased a new stake in Hims & Hers Health in the 3rd quarter worth approximately $28,000. Flagship Harbor Advisors LLC purchased a new stake in Hims & Hers Health in the 4th quarter worth approximately $28,000. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health during the 3rd quarter valued at $28,000. Bogart Wealth LLC grew its stake in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company's stock valued at $29,000 after buying an additional 632 shares during the period. Finally, Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health during the 1st quarter valued at $30,000. 63.52% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the company. Citigroup upgraded Hims & Hers Health from a "sell" rating to a "neutral" rating and upped their price target for the stock from $13.25 to $24.00 in a research note on Tuesday, March 10th. Weiss Ratings restated a "hold (c)" rating on shares of Hims & Hers Health in a research note on Friday, March 27th. Morgan Stanley decreased their price target on Hims & Hers Health from $40.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 24th. Evercore set a $24.00 price target on Hims & Hers Health in a research note on Tuesday, February 24th. Finally, TD Cowen decreased their price target on Hims & Hers Health from $25.00 to $23.00 and set a "hold" rating on the stock in a research note on Friday, March 27th. Three analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health has an average rating of "Hold" and a consensus price target of $31.71.
Get Our Latest Stock Analysis on HIMS
More Hims & Hers Health News
Here are the key news stories impacting Hims & Hers Health this week:
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.
The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
